Mucositis in malignant hematology
1Hematology Unit, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, Rome, Italy. pniscola@gmail.com
Abstract:
Mucosal barrier injury (MBI), also known as mucositis, is the result of the cytotoxic effects of many treatments given for hematological malignancies (HMs) and represents a major source of potentially devastating clinical complications and negative consequences afflicting the patient's management, such as a longer hospitalization, the need of analgesic and total parenteral nutrition use, and increased costs. The available measures for the prevention and treatment of MBI have been substantially limited to the control of pain, infection, bleeding and nutrition. However, in the last decade, a better insight into the complex pathogenesis of MBI has led to the development of novel therapeutic options, such as palifermin, which has been one of the major breakthroughs in the management of this condition, potentially allowing a targeted approach to MBI. Nevertheless, and despite these significant advances, MBI still remains a significant clinical problem in the management of HM and an important burden of sufferance for afflicted patients.
Insights
Mucosal barrier injury (MBI), or mucositis, is a severe side effect of cancer treatments. While palifermin offers a targeted approach, MBI remains a significant clinical challenge for hematological malignancy patients.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Mucosal barrier injury (MBI), also known as mucositis, is a common and debilitating side effect of treatments for hematological malignancies (HMs).
- MBI leads to significant clinical complications, including prolonged hospitalization, increased pain, need for nutritional support, and higher healthcare costs.
- Current management strategies for MBI are largely supportive, focusing on pain, infection, bleeding, and nutrition control.
Purpose of the Study:
- To review the current understanding of MBI pathogenesis in HM patients.
- To highlight advancements in MBI management, particularly novel therapeutic options.
- To emphasize the ongoing challenges and future directions in addressing MBI.
Main Methods:
- Literature review of MBI pathogenesis and treatment in hematological malignancies.
- Analysis of the impact of cytotoxic therapies on the mucosal barrier.
- Evaluation of emerging therapeutic strategies, including targeted agents like palifermin.
Main Results:
- Cytotoxic treatments for HMs induce significant MBI, impacting patient outcomes.
- Palifermin represents a breakthrough, offering a targeted therapeutic approach to MBI.
- Despite advances, MBI remains a substantial clinical problem and a source of patient suffering.
Conclusions:
- A deeper understanding of MBI pathogenesis has enabled the development of targeted therapies.
- Palifermin has shown promise in managing MBI, representing a significant advancement.
- Further research and therapeutic innovations are crucial to alleviate the burden of MBI in HM patients.
